Top

Published in:

Open Access 01-12-2015 | Research

Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array

Authors: Till Braunschweig, Joon-Yong Chung, Chel Hun Choi, Hanbyoul Cho, Qing-Rong Chen, Ran Xie, Candice Perry, Javed Khan, Stephen M Hewitt

Published in: Diagnostic Pathology | Issue 1/2015

Abstract

Background

The differential diagnosis of benign and malignant effusion is often hampered by low cell content or insufficiently preserved tumor cells. In this study, we evaluated the combined diagnostic value of six tumor markers measured by well-based reverse-phase protein array (RPPA) for diagnosis of malignant effusion.

Methods

A total of 114 patients (46 with malignant effusions, 32 with probable malignant effusions, and 36 with benign effusions) were enrolled. Expressional levels of MUC1, EMA, Pan-CK, HSP90, TGF-β and CA125 were determined by well-based RPPA.

Results

Median relative expression of MUC1, Pan-CK and EMA were significantly higher in malignant effusion than those in probable malignant or benign (p < 0.001, p = 0.003, p < 0.001, respectively), whereas the level of TGF-β in malignant effusions were significantly lower than that in the other groups (p = 0.005). For predicting malignancy, EMA presented the best areas under the curve of 0.728 followed by MUC1 of 0.701. The sensitivity of 52.0% for MUC1 and 48.0% for EMA were not better than cytology. However, sensitivity, negative predictive value, and accuracy of the tumor marker panel were better than cytology by 14.7%, 7.5%, and 6.1%, respectively.

Conclusions

Tumor marker panel measured by well-based RPPA showed values in the differential diagnosis between benign and malignant effusions. Further large scale studies need to be performed to evaluate the utility of this panel of markers.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1433424467160224

Available only for authorised users

Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4(3):320–4.PubMed

Ong KC, Indumathi V, Poh WT, Ong YY. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. Singapore Med J. 2000;41(1):19–23.PubMed

Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111(1):106–9.PubMed

Hewitt SM. Design, construction, and use of tissue microarrays. Methods Mol Biol. 2004;264:61–72.PubMed

Metzgeroth G, Kuhn C, Schultheis B, Hehlmann R, Hastka J. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. Cytopathology. 2008;19(4):205–11.CrossRefPubMed

Hoermann R, Gerbes AL, Spoettl G, Jungst D, Mann K. Immunoreactive human chorionic gonadotropin and its free beta subunit in serum and ascites of patients with malignant tumors. Cancer Res. 1992;52(6):1520–4.PubMed

Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117(3):215–20.PubMed

Chen SJ, Wang SS, Lu CW, Chao Y, Lee FY, Lee SD, et al. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites. J Gastroenterol Hepatol. 1994;9(4):396–400.PubMed

Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50(6):1774–8.PubMed

10.

Gericke B, Raila J, Sehouli J, Haebel S, Konsgen D, Mustea A, et al. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer. 2005;5:133.CrossRefPubMedCentralPubMed

11.

Hernandez L, Espasa A, Fernandez C, Candela A, Martin C, Romero S. CEA and CA 549 in serum and pleural fluid of patients with pleural effusion. Lung Cancer. 2002;36(1):83–9.CrossRefPubMed

12.

Li CS, Cheng BC, Ge W, Gao JF. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. Int J Clin Pract. 2007;61(3):444–8.PubMed

13.

Jiang H, Gupta R, Somma J. EZH2, a unique marker of malignancy in effusion cytology. Diagn Cytopathol. 2014;42(2):111–6.PubMed

14.

Hyun TS, Barnes M, Tabatabai ZL. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology. Acta Cytol. 2012;56(5):527–32.PubMed

15.

Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15–3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126(6):1757–63.PubMed

16.

Kremer R, Best LA, Savulescu D, Gavish M, Nagler RM. Pleural fluid analysis of lung cancer vs benign inflammatory disease patients. Br J Cancer. 2010;102(7):1180–4.PubMedCentralPubMed

17.

Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85.PubMedCentralPubMed

18.

Murugan P, Siddaraju N, Habeebullah S, Basu D. Immunohistochemical distinction between mesothelial and adenocarcinoma cells in serous effusions: a combination panel-based approach with a brief review of the literature. Indian J Pathol Microbiol. 2009;52(2):175–81.PubMed

19.

Zimmerman RL, Fogt F, Goonewardene S. Diagnostic value of a second generation CA 15–3 antibody to detect adenocarcinoma in body cavity effusions. Cancer. 2000;90(4):230–4.CrossRefPubMed

20.

Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell. 1996;7(4):565–77.PubMedCentralPubMed

21.

Janzi M, Odling J, Pan-Hammarstrom Q, Sundberg M, Lundeberg J, Uhlen M, et al. Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics. 2005;4(12):1942–7.PubMed

22.

Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, et al. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics. 2008;8(15):3051–60.CrossRefPubMedCentralPubMed

23.

Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. Chest. 2003;124(3):978–83.PubMed

24.

Chung JY, Lee SJ, Kris Y, Braunschweig T, Traicoff JL, Hewitt SM. A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl. 2008;2(10–11):1539–47.PubMedCentralPubMed

25.

Chung JY, Braunschweig T, Hong SM, Kwon DS, Eo SH, Cho H, et al. Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array. Proteome Sci. 2014;12:27.PubMedCentralPubMed

26.

Williams R, Chung JY, Ylaya K, Whiteley G, Hewitt SM. Characterizations and validations of novel antibodies toward translational research. Proteomics Clin Appl. 2010;4(6–7):618–25.PubMed

27.

Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer. 1999;86(12):2668–73.CrossRefPubMed

28.

Thomas SC, Davidson LR, McKean ME. An investigation of adequate volume for the diagnosis of malignancy in pleural fluids. Cytopathology. 2011;22(3):179–83.CrossRefPubMed

29.

Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009;135(4):999–1001.PubMed

30.

Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010;137(1):68–73.PubMed

31.

Sallach SM, Sallach JA, Vasquez E, Schultz L, Kvale P. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest. 2002;122(6):1913–7.PubMed

32.

Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83(2):235–50.PubMed

33.

Ensani F, Nematizadeh F, Irvanlou G. Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions. Pol J Pathol. 2011;62(2):95–100.PubMed

34.

Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, et al. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011;178(2):548–71.PubMedCentralPubMed

35.

Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res. 2013;19(24):6976–86.PubMed

36.

Charboneau L, Tory H, Chen T, Winters M, Petricoin 3rd EF, Liotta LA, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002;1(3):305–15.PubMed

37.

Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014;1846(2):539–46.PubMed

38.

Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 1999;81(6):1059–65.PubMedCentralPubMed

39.

Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, et al. Diagnostic value of CYFRA 21–1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119(4):1138–42.PubMed

40.

Garcia-Pachon E, Padilla-Navas I, Dosda MD, Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest. 1997;111(3):643–7.PubMed

41.

Riedel U, Schonfeld N, Savaser A, Serk M, Loddenkemper R. Diagnostic value of the tumor markers TPA-M, CYPFRA 21–1 and CEA in pleural effusion. Prospective comparison of thoracoscopic investigations in patients with pleural effusion. Pneumologie. 1999;53(10):471–6.CrossRefPubMed

42.

Riantawan P, Sangsayan P, Bangpattanasiri K, Rojanaraweewong P. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration. 2000;67(1):24–9.CrossRefPubMed

43.

Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HM, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer. 1981;44(1):85–90.PubMedCentralPubMed

44.

Cordell J, Richardson TC, Pulford KA, Ghosh AK, Gatter KC, Heyderman E, et al. Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer. 1985;52(3):347–54.PubMedCentralPubMed

45.

Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17–23, 1996. Tumour Biol. 1998;19 Suppl 1:1–20.PubMed

46.

Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol. 2004;17(2):180–8.PubMed

Title: Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array
Authors: Till Braunschweig
Joon-Yong Chung
Chel Hun Choi
Hanbyoul Cho
Qing-Rong Chen
Ran Xie
Candice Perry
Javed Khan
Stephen M Hewitt
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-015-0290-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array

Abstract

Background

Methods

Results

Conclusions

Virtual slides

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Virtual slides

Please log in to get access to this content

Other articles of this Issue 1/2015

Loss of heterozygosity at D8S262: an early genetic event of hepatocarcinogenesis

3-dimensional digital reconstruction of the murine coronary system for the evaluation of chronic allograft vasculopathy

FusionCancer: a database of cancer fusion genes derived from RNA-seq data

A case report of retiform hemangioendothelioma as pleural nodules with literature review

A case report of a rare intramuscular granular cell tumor

Hodgkin’s lymphoma is a rare form of clonal haematological non-mast cell disease in systemic mastocytosis